First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,…
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and…
Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by…
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of…
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated…
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt…
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of…
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable…
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and…
December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed…